The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Efficacy and Safety of First-line Avelumab Treatment in Patients With Stage IV Metastatic Merkel Cell Carcinoma: A Preplanned Interim Analysis of a Clinical Trial
Open accessAbstract
Importance: Merkel cell carcinoma (MCC) is an aggressive skin cancer that is associated with poor survival outcomes in patients with distant metastatic disease. Results of part A of the JAVELIN Merkel 200 trial (avelumab in patients with Merkel cell carcinoma) showed that avelumab, an anti-programmed cell death ligand 1 (PD-L1) antibody, demonstrated efficacy in second-line or later treatment of patients with metastatic MCC (mMCC). Objective: To evaluate the efficacy and safety of avelumab as first-line treatment for patients with distant mMCC. Design, Setting, and Participants: JAVELIN Merkel 200 part B is an international, multicenter, single-arm, open-label clinical trial of first-line avelumab monotherapy. Eligible patients were adults with mMCC who had not received prior systemic treatment for metastatic disease. Patients were not selected for PD-L1 expression or Merkel cell polyomavirus status. Data were collected from April 15, 2016, to March 24, 2017, and enrollment is ongoing. Interventions: Patients received avelumab, 10 mg/kg, by 1-hour intravenous infusion every 2 weeks until confirmed disease progression, unacceptable toxic effects, or withdrawal occurred. Main Outcomes and Measures: Tumor status was assessed every 6 weeks and evaluated by independent review committee per Response Evaluation Criteria in Solid Tumors version 1.1. The primary end point was durable response, defined as an objective response with a duration of at least 6 months. Secondary end points include best overall response, duration of response, progression-free survival, safety, and tolerability. Results: As of March 24, 2017, 39 patients were enrolled (30 men and 9 women; median age, 75 years [range, 47-88 years]), with a median follow-up of 5.1 months (range, 0.3-11.3 months). In a preplanned analysis, efficacy was assessed in 29 patients with at least 3 months of follow-up; the confirmed objective response rate was 62.1% (95% CI, 42.3%-79.3%), with 14 of 18 responses (77.8%) ongoing at the time of analysis. In responding patients, the estimated proportion with duration of response of at least 3 months was 93% (95% CI, 61%-99%); duration of response of at least 6 months, 83% (95% CI, 46%-96%). First-line avelumab treatment was generally well tolerated, and no treatment-related deaths or grade 4 adverse events occurred. Conclusions and Relevance: High rates of response to first-line avelumab therapy in patients with distant mMCC build on previously reported antitumor activity after second-line or later treatment, and maturing progression-free survival data suggest that responses are durable. These data further support avelumab's approval in the United States and European Union and use as a standard-of-care treatment for mMCC. Trial Registration: clinicaltrials.gov Identifier: NCT02155647.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The National Comprehensive Cancer Network: Present and future directions
McGivney, W. T. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980515)82:10+<2057::aid-cncr14>3.0.co;2-a · Cited by 16,766
PD-1 Blockade with pembrolizumab in advanced Merkel-cell carcinoma
Nghiem, P. T., Bhatia, S., Lipson, E. J., Kudchadkar, R. R., Miller, N. J., Annamalai, L., Berry, S., Chartash, E. K., Daud, A., Fling, S. P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603702 · Cited by 1,258
Kaufman, H. L., Russell, J., Hamid, O., Bhatia, S., Terheyden, P., D'Angelo, S. P., Shih, K. C., Lebbé, C., Linette, G. P., Milella, M., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30364-3 · Cited by 1,236
Self-citationMerkel cell carcinoma: Epidemiology, prognosis, therapy and unmet medical needs
Schadendorf, D., Lebbé, C., zur Hausen, A., Avril, M.-F., Hariharan, S., Bharmal, M., & Becker, J. C. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2016.10.022 · Cited by 397
Self-citationLipson, E. J., Vincent, J. G., Loyo, M., Kagohara, L. T., Luber, B. S., Wang, H., Xu, H., Nayar, S. K., Wang, T. S., Sidransky, D., et al. (2013) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0034 · Cited by 378
Kaufman, H. L., Russell, J. S., Hamid, O., Bhatia, S., Terheyden, P., D’Angelo, S. P., Shih, K. C., Lebbé, C., Milella, M., Brownell, I., et al. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0310-x · Cited by 334
Merkel Cell Carcinoma, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology
Bichakjian, C. K., Olencki, T., Aasi, S. Z., Alam, M., Andersen, J. S., Blitzblau, R., Bowen, G. M., Contreras, C. M., Daniels, G. A., Decker, R., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0055 · Cited by 319
Iyer, J. G., Blom, A., Doumani, R., Lewis, C., Tarabadkar, E. S., Anderson, A., Ma, C., Bestick, A., Parvathaneni, U., Bhatia, S., et al. (2016) · Cancer Medicine · doi:10.1002/cam4.815 · Cited by 260
Nghiem, P., Kaufman, H. L., Bharmal, M. F., Mahnke, L. A., Phatak, H. M., & Becker, J. C. (2017) · Future Oncology · doi:10.2217/fon-2017-0072 · Cited by 156
Self-citationTopalian, S. L., Bhatia, S., Hollebecque, A., Awada, A. H., de Boer, J. P., Kudchadkar, R. R., Gonçalvès, A., Delord, J., Martens, U. M., López-Picazo, J. M., et al. (2017) · Cancer Research · doi:10.1158/1538-7445.am2017-ct074 · Cited by 150
Cited by
Brahmer, J. R., Abu-Sbeih, H., Ascierto, P. A., Brufsky, J., Cappelli, L. C., Cortazar, F. B., Gerber, D. E., Hamad, L., Hansen, E., Johnson, D. B., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002435 · Cited by 917
Wang, Y., Zhou, S., Yang, F., Qi, X., Wang, X., Guan, X., Shen, C., Duma, N., Vera Aguilera, J., Chintakuntlawar, A., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.0393 · Cited by 862
Regulatory mechanisms of PD-1/PD-L1 in cancers
Lin, X., Kang, K., Chen, P., Zeng, Z., Li, G., Xiong, W., Yi, M., & Xiang, B. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02023-w · Cited by 784
PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations
Jiang, Y., Chen, M., Nie, H., & Yuan, Y. (2019) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2019.1571892 · Cited by 640
Nghiem, P., Bhatia, S., Lipson, E. J., Sharfman, W. H., Kudchadkar, R. R., Brohl, A. S., Friedlander, P. A., Daud, A., Kluger, H. M., Reddy, S. A., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.01896 · Cited by 396
Metadata
- Authors
- D’Angelo, S. P., Russell, J., Lebbé, C., Chmielowski, B., Gambichler, T., Grob, J.-J., Kiecker, F., Rabinowits, G., Terheyden, P., Zwiener, I., Bajars, M., Hennessy, M., & Kaufman, H. L.
- Venue
- JAMA Oncology
- Publisher
- American Medical Association (AMA)
- Published
- 2018-09-13
- Volume
- 4
- Issue
- 9
- Pages
- e180077
- ISSN
- 2374-2437 (ISSN-L)
- OpenAlex
- W2792936868
- Cited by
- 377
- References
- 13
- FWCI
- 20.39
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy and Safety of First-line Avelumab Treatment in Patients With Stage IV Metastatic Merkel Cell Carcinoma: A Preplanned Interim Analysis of a Clinical Trial. https://app.cochat.ai/papers/10.1001/jamaoncol.2018.0077
- The paper
- D’Angelo, S. P., Russell, J., Lebbé, C., Chmielowski, B., Gambichler, T., Grob, J.-J., Kiecker, F., Rabinowits, G., Terheyden, P., Zwiener, I., Bajars, M., Hennessy, M., & Kaufman, H. L. (2018). Efficacy and Safety of First-line Avelumab Treatment in Patients With Stage IV Metastatic Merkel Cell Carcinoma: A Preplanned Interim Analysis of a Clinical Trial. JAMA Oncology. https://doi.org/10.1001/jamaoncol.2018.0077
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.